A Study of Izalontamab Brengitecan or Chemotherapy in People With Urothelial Cancer

Full Title

IZABRIGHT-BLADDER01: A Randomized, Open-Label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-Based Chemotherapy for Metastatic Urothelial Cancer in Participants with Disease Progression on or After an Immunotherapy-Based Treatment

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Jonathan Rosenberg’s office at 646-422-4461.

Protocol

26-017

Phase

Phase II/III (phases 2 and 3 combined)

Disease Status

Relapsed or Refractory

Investigator

Jonathan E. Rosenberg

Co-Investigators

Scot Niglio

Diseases

Genitourinary Cancer › Bladder Cancer

Locations

Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau

ClinicalTrials.gov ID

NCT07106762

ClinicalTrials.gov

Visit ClinicalTrials.gov for full clinical trial description